Arrowhead Pharmaceuticals Inc

Arrowhead CFO’s structured $1.5 M insider sale confirms confidence in gene‑silencing growth, offering investors insight into portfolio strategy and market positioning.

Arrowhead Pharmaceuticals’ insider buying and $700 M capital raise signal rising confidence in its RNAi obesity pipeline and global market‑access strategy, hinting at strong future upside.